Evaluation of Immunological Reconstitution After Haploidentical Bone Marrow Transplantation

Armando Santoro, MD23 enrolled

Overview

Evaluation of immunological reconstitution after haploidentical BMT using a nonmyeloablative preparative regimen and post-transplant cyclophosphamide in patients with poor prognosis lymphoma

Study Type

OBSERVATIONAL

Enrollment

Conditions

Lymphoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with lymphoma (any histology) relapsed after high dose chemotherapy and in partial remission, complete remission or stable disease after the last CT line that * Signed informed consent to perform an haploidentical allo-BMT using a nonmyeloablative preparative regimen and post-transplant cyclophosphamide Exclusion Criteria: none

Locations (1)

Istituto Clinico Humanitas

Rozzano, MI, Italy

Outcomes

Primary Outcomes

Evaluation of T lymphocytes and NK cells absolute number

Time frame: 1 year

Secondary Outcomes

Evaluation of discrete T-cells populations

Evaluation, by flow cytometry, of discrete T cell populations, including CD4+ and CD8+ TN, TSCM, TCM and TEM, NK and NKT cells, B cells, dendritic cell subsets

Time frame: 1 year

Evaluation of antigen-specific T cell populations

Evaluation of antigen-specific T cell frequency towards CMV, EBV and influenza virus by MHC tetramers

Time frame: 1 year

Evaluation of antigen-specific T lymphocyte's functionality

antigen-specific T lymphocyte's functionality towards tumor cell line evaluated using a degranulation assay

Time frame: 1 year

Evaluation of cytokines production by IL-2 and anti-CD16 activated NK cells

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.